Home > Diseases and Conditions > Hemolytic disease of the newborn

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.

A.D.A.M. Medical Encyclopedia.

Hemolytic disease of the newborn

HDN; Erythroblastosis fetalis

Last reviewed: November 14, 2011.

Hemolytic disease of the newborn (HDN) is a blood disorder in a fetus or newborn infant. In some infants, it can be life threatening.

This article provides a general overview. For more detailed information see the specific disorder:

Causes, incidence, and risk factors

HDN may develop when a mother and her unborn baby have different blood types (called "incompatibility"). The mother produces substances called antibodies that attack the developing baby's red blood cells.

The most common form of HDN is ABO incompatibility, which is usually not very severe. Other, less common types may cause more severe problems.

The least common form is Rh incompatibility, which can almost always be prevented. When this form does occur, it can cause very severe anemia in the baby.

Symptoms

HDN can destroy the newborn baby's blood cells very quickly, which can cause symptoms such as:

Signs and tests

Signs of HDN include:

  • Anemia or low blood count
  • Enlarged liver or spleen
  • Hydrops (fluid throughout the body's tissues, including in the spaces containing the lungs, heart, and abdominal organs)--which can lead to heart failure from too much fluid

Which tests are done depends on the type of blood group incompatibility and the severity of symptoms, but may include:

  • Complete blood count and immature red blood cell (reticulocyte) count
  • Bilirubin level
  • Blood typing

Treatment

After birth, a transfusion may need to be performed.

Infants with mild HDN may be treated with:

  • Drugs used to treat allergic reactions (antihistamines)
  • Drugs used to treat swelling and allergies (steroids)
  • Feeding and fluids (hydration)
  • Fluids given through a vein (intravenously)
  • Light therapy using bilirubin lights
  • Medicines to raise blood pressure if it drops too low

Expectations (prognosis)

The severity of this condition can vary. Some babies have no symptoms. In other cases, problems such as hydrops can cause the baby to die before, or shortly after birth. Severe HDN may be treated before birth by intrauterine transfusion.

Prevention

The most severe form of this disease, which is caused by Rh incompatibility, can be prevented if the mother takes a medicine called RhoGAM at certain times during and after her pregnancy. If you have had a baby with this disease, talk with your doctor if you plan to have another baby.

References

  1. Gruslin AM, Moore TR. Erythroblastosis fetalis. In: Martin R, Fanaroff A, Walsh M, eds. Neonatal-Perinatal Medicine. 9th ed. Philadelphia, Pa: Mosby Elsevier; 2011.
  2. Cohen DW. Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues. UpToDate, Waltham, MA. Nov 2009.

Review Date: 11/14/2011.

Reviewed by: Kimberly G. Lee, MD, MSc, IBCLC, Associate Professor of Pediatrics, Division of Neonatology, Medical University of South Carolina, Charleston, SC. Review Provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

What works?

  • Single versus double volume exchange transfusion in jaundiced newborn infantsSingle versus double volume exchange transfusion in jaundiced newborn infants
    Extremely high levels of bilirubin (severe jaundice) can lead to brain damage. Severe jaundice in newborns can occur as a result of a variety of causes including rhesus hemolytic disease, ABO incompatibility, atypical antibodies etc. Removal of blood from the affected infant and replacing with fresh blood from the blood bank (exchange transfusion) is used as a treatment for severe jaundice in newborn infants. The affected infant's blood is removed in small portions and equal volume of blood is replaced during exchange transfusion. Traditionally twice the blood volume of baby is removed and the replaced with fresh blood. Exchange transfusion has been shown to reduce brain damage in severely jaundiced babies; however, exchange transfusion is associated with serious adverse events including death. It is likely that the complications of exchange transfusion would increase with amount of blood exchanged. This review was undertaken to examine if single volume (removal of blood equivalent to the blood volume of the baby) is as effective as double volume (removal of twice blood volume of the baby) in reducing the brain damage and bilirubin levels in newborn infants with severe jaundice. Only one randomised trial fulfilled the criteria for inclusion in the analysis. This study compared single and double volume exchange transfusion in jaundice due to ABO hemolytic jaundice. The study found no significant difference in bilirubin levels following exchange. This study did not look at any long term neurodevelopmental outcome (brain damage). Based on the available data, there is insufficient evidence to support or refute the use of single volume exchange transfusion as opposed to double volume exchange transfusion in jaundiced newborns.
See all (2) ...

Figures

  • Intrauterine transfusion.
    Antibodies.

Learn about...

  • Making smart health choicesMaking smart health choices
    Develop the skills to assess health advice and make better-informed decisions about your health and managing illness.

MedlinePlus.gov links to free, reliable, up-to-date health information from the National Institutes of Health (NIH) and other trusted health organizations.

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk